Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?


Çetin B., Wabl C. A., GÜMÜŞAY Ö.

FUTURE ONCOLOGY, vol.18, no.39, pp.4235-4238, 2022 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 18 Issue: 39
  • Publication Date: 2022
  • Doi Number: 10.2217/fon-2022-0668
  • Journal Name: FUTURE ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.4235-4238
  • Keywords: advanced prostate cancer, homologous recombination repair, PARP inhibitors, INCREASED SURVIVAL, ENZALUTAMIDE, PREDNISONE, MUTATIONS, ACETATE, MEN
  • Ondokuz Mayıs University Affiliated: No